Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
3.39 (1y: +19%)
Market Cap 470.3 M P/E(ttm)
Enterprise Value 432.88 M P/B 12.50
AVNR- NAS (USA)
AVANIR Pharmaceuticals
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$3.39
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry		 vs
history
Cash to Debt 2.454
AVNR's Cash to Debt is ranked lower than
233645% of the 428 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.30 vs. AVNR: 2.454 )
AVNR' s 10-Year Cash to Debt Range
Min: 0.84   Max: No Debt
Current: 2.45
Equity to Asset 0.428
AVNR's Equity to Asset is ranked lower than
258398% of the 387 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. AVNR: 0.428 )
AVNR' s 10-Year Equity to Asset Range
Min: -0.53   Max: 0.89
Current: 0.43
-0.53
0.89
F-Score: 2
Z-Score: -2.53
M-Score: -3.28
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry		 vs
history
Operating margin (%) -141.50
AVNR's Operating margin (%) is ranked lower than
303951% of the 329 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.90 vs. AVNR: -141.50 )
AVNR' s 10-Year Operating margin (%) Range
Min: -962.7   Max: 35.1
Current: -141.5
-962.7
35.1
Net-margin (%) -144.7
AVNR's Net-margin (%) is ranked lower than
304878% of the 328 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. AVNR: -144.7 )
AVNR' s 10-Year Net-margin (%) Range
Min: -952.7   Max: 1.7
Current: -144.7
-952.7
1.7
ROE (%) -162.2
AVNR's ROE (%) is ranked lower than
308642% of the 324 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.40 vs. AVNR: -162.2 )
AVNR' s 10-Year ROE (%) Range
Min: -2240.7   Max: 1
Current: -162.2
-2240.7
1
ROA (%) -69.5
AVNR's ROA (%) is ranked lower than
305810% of the 327 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. AVNR: -69.5 )
AVNR' s 10-Year ROA (%) Range
Min: -87.5   Max: 0.9
Current: -69.5
-87.5
0.9
Revenue Growth (%) 57.8
AVNR's Revenue Growth (%) is ranked lower than
434782% of the 230 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.10 vs. AVNR: 57.8 )
AVNR' s 10-Year Revenue Growth (%) Range
Min: -43.8   Max: 57.8
Current: 57.8
-43.8
57.8
EBITDA Growth (%) 12.3
AVNR's EBITDA Growth (%) is ranked lower than
724637% of the 138 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.60 vs. AVNR: 12.3 )
AVNR' s 10-Year EBITDA Growth (%) Range
Min: -38   Max: 12.7
Current: 12.3
-38
12.7
EPS Growth (%) 12.6
AVNR's EPS Growth (%) is ranked lower than
757575% of the 132 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.30 vs. AVNR: 12.6 )
AVNR' s 10-Year EPS Growth (%) Range
Min: 0   Max: 110.1
Current: 12.6
0
110.1
» AVNR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q4 2011

AVNR Guru Trades in Q4 2011

Louis Moore Bacon Sold Out
» More
Q3 2012

AVNR Guru Trades in Q3 2012

Steven Cohen 401,514 sh (New)
» More
Q4 2012

AVNR Guru Trades in Q4 2012

Steven Cohen 827,300 sh (+106.05%)
» More
Q1 2013

AVNR Guru Trades in Q1 2013

Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AVNR



No Insider Trades Found!

Top Ranked Articles about AVANIR Pharmaceuticals

Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse Inc, and NewLink Genetics Corp.
June 30, 2012
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse Inc, and NewLink Genetics Corp. Universal Insurance Holdings, Inc. (UVE): CEO, 10% Owner Bradley I Meier sold 1,500,000 Shares Read more...

Ratios

vs
industry		 vs
history
P/B 12.50
AVNR's P/B is ranked lower than
238095% of the 420 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.51 vs. AVNR: 12.50 )
AVNR' s 10-Year P/B Range
Min: 0.78   Max: 202.67
Current: 12.5
0.78
202.67
P/S 7.90
AVNR's P/S is ranked lower than
231481% of the 432 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. AVNR: 7.90 )
AVNR' s 10-Year P/S Range
Min: 2.15   Max: 166.67
Current: 7.9
2.15
166.67
EV-to-EBIT 90.9
AVNR's EV-to-EBIT is ranked lower than
273224% of the 366 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.66 vs. AVNR: 90.9 )
AVNR' s 10-Year EV-to-EBIT Range
Min: 26.6   Max: 123.5
Current: 90.9
26.6
123.5

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 21.3
AVNR's Price/Net Cash is ranked lower than
751879% of the 133 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.60 vs. AVNR: 21.3 )
AVNR' s 10-Year Price/Net Cash Range
Min: 1.6   Max: 107
Current: 21.3
1.6
107
Price/Net Current Asset Value 85
AVNR's Price/Net Current Asset Value is ranked lower than
255754% of the 391 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.80 vs. AVNR: 85 )
AVNR' s 10-Year Price/Net Current Asset Value Range
Min: 57.5   Max: 618
Current: 85
57.5
618
Price/Tangible Book 12.6
AVNR's Price/Tangible Book is ranked lower than
257732% of the 388 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. AVNR: 12.6 )
AVNR' s 10-Year Price/Tangible Book Range
Min: 1.4   Max: 58.9
Current: 12.6
1.4
58.9
Price/Median PS Value 0.4
AVNR's Price/Median PS Value is ranked lower than
243902% of the 410 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. AVNR: 0.4 )
AVNR' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 3.9
Current: 0.4
0.3
3.9
Earnings Yield (Greenblatt) 1.10
AVNR's Earnings Yield (Greenblatt) is ranked lower than
277008% of the 361 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. AVNR: 1.10 )
AVNR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 3.8
Current: 1.1
0.8
3.8
Forward Rate of Return (Yacktman) 6
AVNR's Forward Rate of Return (Yacktman) is ranked lower than
704225% of the 142 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.10 vs. AVNR: 6 )
AVNR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -64.6   Max: -49.3
Current: 6
-64.6
-49.3

Business Description

Avanir Pharmaceuticals Inc. was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a pharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an innovative combination of two well-characterized components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.
Company Website
SEC Reports
Industry: Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX
Traded in other countries:AV2B.Germany
» More Articles for AVNR

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Danaher Corporation, Orbitz Worldwide Inc., 3D Systems Corporation and A May 20 2013 
Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse I Jun 30 2012 
Weekly CEO Sells Highlight: KIT digital Inc, Avanir Pharmaceuticals Inc, J & J Snack Foods Corp. and Nov 26 2011 
Options V: Short-Term Strategy – Earning Money on Volatility Oct 19 2011 
Avanir Pharmaceuticals Reports Operating Results (10-Q) Feb 07 2011 
Avanir Pharmaceuticals Reports Operating Results (10-K) Dec 08 2010 
Avanir Pharmaceuticals (AVNR) President and CEO Keith Katkin sells 195,300 Shares Dec 03 2010 
Weekly CEO Sells Highlights: MAC, GNET, ASIA, and AVNR Sep 05 2010 
Avanir Pharmaceuticals (AVNR) President and CEO Keith Katkin sells 102,874 Shares Sep 02 2010 
Avanir Pharmaceuticals Reports Operating Results (10-Q) Aug 05 2010 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial